Results 31 to 40 of about 166,627 (157)

MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine [PDF]

, 2011
Introduction. We previously reported that in HIV-1 infected patients circulating Vdelta1 T lymphocytes (Vδ1) increase and proliferate in vitro in response to Candida albicans (Ca).
GASPARINI, ROBERTO, DURANDO, PAOLO, A. Poggi, M. R. Zocchi, D. Fenoglio, A. Parodi, G. Gabutti   +6 more
core   +3 more sources

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineResearch in context

EBioMedicine, 2023
Summary: Background: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during ...
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, Samantha L. Grimley, James P. Cooney, Samuel J. Redmond, Paula Ellenberg, Kathryn C. Davidson, Francesca L. Mordant, Tim Smith, Marianne Gillard, Ester Lopez, Julie McAuley, Chee Wah Tan, Jing J. Wang, Weiguang Zeng, Mason Littlejohn, Runhong Zhou, Jasper Fuk-Woo Chan, Zhi-wei Chen, Airn E. Hartwig, Richard Bowen, Jason M. Mackenzie, Elizabeth Vincan, Joseph Torresi, Katherine Kedzierska, Colin W. Pouton, Tom P. Gordon, Lin-fa Wang, Stephen J. Kent, Adam K. Wheatley, Sharon R. Lewin, Kanta Subbarao, Amy W. Chung, Marc Pellegrini, Trent Munro, Terry Nolan, Steven Rockman, David C. Jackson, Damian F.J. Purcell, Dale I. Godfrey   +40 more
doaj   +1 more source

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

Vaccines, 2021
Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic.
Eve Versage, Esther van Twuijver, Wim Jansen, Ad Theeuwes, Daphne Sawlwin, Matthew Hohenboken   +5 more
doaj   +1 more source

Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway

eLife, 2020
The squalene-based oil-in-water emulsion (SE) vaccine adjuvant MF59 has been administered to more than 100 million people in more than 30 countries, in both seasonal and pandemic influenza vaccines.
Eui Ho Kim, Matthew C Woodruff, Lilit Grigoryan, Barbara Maier, Song Hee Lee, Pratyusha Mandal, Mario Cortese, Muktha S Natrajan, Rajesh Ravindran, Huailiang Ma, Miriam Merad, Alexander D Gitlin, Edward S Mocarski, Joshy Jacob, Bali Pulendran   +14 more
doaj   +1 more source

Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

Clinical & Translational Immunology, 2021
Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational antigen design through to manufacturability and vaccine efficacy of a prefusion ...
Daniel Watterson, Danushka K Wijesundara, Naphak Modhiran, Francesca L Mordant, Zheyi Li, Michael S Avumegah, Christopher LD McMillan, Julia Lackenby, Kate Guilfoyle, Geert vanAmerongen, Koert Stittelaar, Stacey TM Cheung, Summa Bibby, Mallory Daleris, Kym Hoger, Marianne Gillard, Eve Radunz, Martina L Jones, Karen Hughes, Ben Hughes, Justin Goh, David Edwards, Judith Scoble, Lesley Pearce, Lukasz Kowalczyk, Tram Phan, Mylinh La, Louis Lu, Tam Pham, Qi Zhou, David A Brockman, Sherry J Morgan, Cora Lau, Mai H Tran, Peter Tapley, Fernando Villalón‐Letelier, James Barnes, Andrew Young, Noushin Jaberolansar, Connor AP Scott, Ariel Isaacs, Alberto A Amarilla, Alexander A Khromykh, Judith MA van denBrand, Patrick C Reading, Charani Ranasinghe, Kanta Subbarao, Trent P Munro, Paul R Young, Keith J Chappell   +49 more
doaj   +1 more source

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition [PDF]

, 2016
A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial.
Robert Guroff, Marjorie, Miller, Christopher J, Xiaoying Shen, Ferrari, Guido, Doster, Melvin N, Quinn, David S, Maria G Ferrari, Matthew Blackburn, Roederer, Mario, Binello, Nicolo, Eric P Brown, Koup, Richard A, Tartaglia, Jim, Fourati, Slim, Brandon F Keele, Blackburn, Matthew, Francesca Caccuri, Bailey-Kellogg, Chris, Ma, Zhong-Min, David C Montefiori, Sekaly, Rafick Pierre, Ratto Kim, Silvia, Christopher J Miller, Vaccari, Monica, Michael, Nelson L, David S Quinn, Richard A Koup, Zhong-Min Ma, Mario Roederer, Nicolo Binello, Marjorie Robert-Guroff, Dowell, Karen G, Shen, Xiaoying, Vargas Inchaustegui, Diego A, Amy W Chung, David Venzon, Galit Alter, Billings, Erik, Rao, Mangala, Ma, Zhong Min, Liyanage, Namal PM, Slim Fourati, Massimiliano Bissa, Ratto-Kim, Silvia, Liyanage, Namal P. M., DeVon Thompson, Liang, Frank, Bissa, Massimiliano, Cameron, Mark, Tran B Phan, Schifanella, Luca, Kim, Jerome H, Jerome H Kim, Melvin N Doster, Tomaras, Georgia D, Forthal, Donald N, Franchini, Genoveffa, Susan W Barnett, Vargas-Inchaustegui, Diego A, Robert-Guroff, Marjorie, Adrian McDermott, Phan, Tran B, Stablein, Donald M, Kathryn Foulds, Donaldson, Mitzi, Loré, Karin, Mitzi Donaldson, Ackerman, Margaret E, Namal P M Liyanage, Nelson L Michael, Monica Vaccari, Genoveffa Franchini, Chung, Amy W, Thompson, Devon, Sanjay Phogat, Jim Tartaglia, Erik Billings, Barnett, Susan W, Montefiori, David C, Karin Loré, Foulds, Kathryn, Shari N Gordon, Diego A Vargas-Inchaustegui, Silvia Ratto-Kim, Whitney, Stephen, Pegu, Poonam, Venzon, David, Margaret E Ackerman, Gordon, Shari N, Donald N Forthal, Mark Cameron, Bailey Kellogg, Chris, Sekaly, Rafick-Pierre, Rafick-Pierre Sekaly, Frank Liang, CACCURI, Francesca, Vaniambadi Kalyanaraman, Alter, Galit, Mcdermott, Adrian, Poonam Pegu, Mangala Rao, Georgia D Tomaras, Karen G Dowell, Brown, Eric P, Kalyanaraman, Vaniambadi, Chris Bailey-Kellogg, Phogat, Sanjay, Keele, Brandon F, Luca Schifanella, Ferrari, Maria G, Donald M Stablein, Stephen Whitney, Guido Ferrari, D. Thompson, M. Robert Guroff, J. Tartaglia, Shen, X, S. N. Gordon, M. Rao, M. Roederer, Gordon, SN, Billings, E, K. G. Dowell, M. E. Ackerman, F. Caccuri, S. W. Barnett, Keele, BF, Liyanage, NPM, D. N. Forthal, M. Donaldson, F. Liang, Z. Ma, Cameron, M, M. Bissa, K. Foulds, E. Billings, A. W. Chung, X. Shen, M. Vaccari, L. Schifanella, D. M. Stablein, G. Alter, B. F. Keele, D. A. Vargas Inchaustegui, D. C. Montefiori, N. L. Michael, S. Phogat, G. D. Tomaras, Schifanella, L, Fourati, S, J. H. Kim, C. Bailey Kellogg, S. Whitney, E. P. Brown, Vaccari, M, R. A. Koup, D. Venzon, P. Pegu, M. Cameron, A. Mcdermott, S. Ratto Kim, M. N. Doster, V. Kalyanaraman, T. B. Phan, FERRARI, MARIA GRAZIELLA, N. Binello, D. S. Quinn, G. Franchini, R. Sekaly, M. Blackburn, G. Ferrari, K. Loré, Tomaras, GD, S. Fourati, C. J. Miller, N. P. M. Liyanage   +175 more
core   +2 more sources

The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination

, 2013
Vaccines are the most effective agents to control infections. In addition to the pathogen antigens, vaccines contain adjuvants that are used to enhance protective immune responses. However, the molecular mechanism of action of most adjuvants is ill-known,
M. Taccone, A. Seubert, Taccone M, Caccin P, FALZONI, Simonetta, DONVITO, Giovanna, Montecucco C, Palmieri E, DI VIRGILIO, Francesco, Seubert A., Gallotta M, De Gregorio E, Vono M, S. Falzoni, G. Donvito, M. Gallotta, E. Palmieri, MONTECUCCO, CESARE, Pallaoro M, M. Vono, M. Pallaoro, R. Rappuoli, CACCIN, PAOLA, F. Di Virgilio, E. De Gregorio, Rappuoli R, Seubert A, Di Virgilio F, Donvito G, Falzoni S   +29 more
core   +1 more source

Proportion of pandemic (H1N1) 2009 monovalent vaccine doses administered, by age group and type of vaccine (without adjuvant, black bars; with MF59® adjuvant, gray bars), November 1, 2009–February 28, 2010.

, 2013
Proportion of pandemic (H1N1) 2009 monovalent vaccine doses administered, by age group and type of vaccine (without adjuvant, black bars; with MF59® adjuvant, gray bars), November 1, 2009–February 28, 2010.
Jen-Hsiang Chuang (210836), Wan-Ting Huang (210819), Yi-Chien Chih (387745), Tzu-Lin Liao (387742), Shu-Er Yang (387744), Hsu-Wen Yang (387741), Wan-Jen Wu (387743)   +6 more
core   +1 more source

MF59 Promoted the Combination of CpG ODN1826 and MUC1-MBP Vaccine-Induced Antitumor Activity Involved in the Enhancement of DC Maturation by Prolonging the Local Retention Time of Antigen and Down-Regulating of IL-6/STAT3

, 2022
Our previous study found that CpG oligodeoxynucleotides 1826 (CpG 1826), combined with mucin 1 (MUC1)-maltose-binding protein (MBP) (M-M), had certain antitumor activity.
Jingyue Feng, Yixuan Wu, Jie, Jing, Hongyan Yuan, Liu, Guomu, Jing Jie, Ni, Weihua, Guixiang Tai, Yuan, Hongyan, Tai, Guixiang, Huo, Desheng, Guomu Liu, Feng, Jingyue, Wu, Yixuan, Desheng Huo, Weihua Ni   +15 more
core   +1 more source

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

Viruses, 2022
The global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become more serious because of the continuous emergence of variants of concern (VOC), thus calling for the development ...
Naru Zhang, Qianting Ji, Zezhong Liu, Kaiming Tang, Yubin Xie, Kangchen Li, Jie Zhou, Sisi Li, Haotian Shang, Zecan Shi, Tianyu Zheng, Jiawei Yao, Lu Lu, Shuofeng Yuan, Shibo Jiang   +14 more
doaj   +1 more source